Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Coherus's Neulasta biosimilar UDENYCA sales ~37M in 1st 3 months of sales and most likely over $200M for the year. That's a wow in my book.

Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA™ Net Sales

GlobeNewswire•April 5, 2019

REDWOOD CITY, Calif., April 05, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that UDENYCA™ preliminary unaudited net sales for the quarter that ended March 31, 2019 are expected to be in the range of $36.0 million to $38.0 million. Coherus will not disclose topline gross sales, discounts, or gross-to-net data until these data are reported in its Form 10-Q for the quarter ended March 31, 2019.
Coherus introduced­­ UDENYCA™ (pegfilgrastim-cbqv) in the U.S. marketplace on January 3, 2019 with a comprehensive launch across all segments including 340B hospitals, non-340B hospitals and clinics.

Bodes well for Rolontis.PR came out at market close. Will be interesting to see how the Street reacts to it on Monday or was the cat out of the bag already (I haven't checked)